News

Acino wins Product of the Year at the Panacea awards, Ukraine’s most prestigious pharmaceutical industry accolade

Thursday 28th October 2021

News Image

The award went to one of Acino’s antipsychotic medicines. The product is manufactured at Pharma Start, Acino’s pharmaceutical plant in Ukraine, which is EU GMP-certified and equipped with a modern research and development laboratory for generics.

“Our product is the class market leader among antipsychotics and is prescribed daily by doctors for the treatment of schizophrenia, bipolar affective disorder and depressive episodes. I would like to thank the healthcare professionals and psychiatrists in particular, for your care for patients suffering from these devastating mental disorders. I am proud of our broad product portfolio at Acino, especially in the area of psychiatry, which no other company in Ukraine can offer. I am proud of our team and their professionalism. This award is for all of you!” – Oksana Selezneva, Brand Manager.

The Acino team at the awards ceremony.

This is the second time this product wins the Product of the Year award at the Panacea Awards since 2018.

Twelve other Acino products in Ukraine have also won Product of the Year awards in the past years. Moreover, Acino won two more Panacea awards in 2020 for its contribution to the development of the educational and social projects Auditorium of Dreams and Your Unlimited World.

These awards are a testament to the high quality of Acino’s manufacturing processes and its social and healthcare focus in Ukraine.

About the awards

Panacea is one of the most prestigious competitions of the Ukrainian pharmaceutical industry. First launched in 1999, the organisers analyse the activities of the pharmaceutical market, determine the best products and services as chosen by consumers, acknowledge industry professionals and their achievements.

The basis of the competition and its main component are independent analyses and market research provided by the current partners of the competition: MASMI, QuintilesIMS, SMD, BUSINESS CREDIT, NIELSEN, UMG.